Super Session 3 – Vaccine Crosslinks: From Cancer to COVID

Super Session hosted by Norway, rising star of rare diseases

28 September 2022

16:00 - 17:00 Plenary Room
Super Session hosted by Norway, rising star of rare diseases

Super Session 3 – Vaccine Crosslinks: From Cancer to COVID

16:00 - 17:00 Plenary Room

Immune links between cancer and infectious diseases have long been evident, and have created the foundation for preventive, treatment-based, and tumor-specific cancer vaccines using technology originally positioned for infectious diseases. Likewise, since the start of the COVID-19 pandemic, companies globally have pivoted and reassigned their R&D and, as a result, we now have numerous breakthroughs, technology applications, and success stories of mRNA COVID-19 vaccines originating from the oncology space.

The ability for our industry to rapidly come together during a pandemic, across sectors, indications, and stages has shown that, big or small, the mutual need for one another exists. How do we continue to build a future of mutually stimulating approaches to infectious disease, immunology, oncology, and technology? We do this by connecting experts, by working to jointly to increase overall understanding of immune modulation and response, and by using technology such as ML / AI to identify and prioritize the selection antigenic determinants. We do this through collaboration.

Norway has proven to be leader in oncology, immunology – and in both answering today’s pandemic needs, as well as working towards the possible pandemics of tomorrow. In this session, our Norwegian partners will lead the discussion on where this road is headed: what can we expect, what do we need, and how can we collaborate for the best possible outcomes?

Hosted by:

Norway

Norway

Oslo Cancer Cluster

Oslo Cancer Cluster

The Life Science Cluster

The Life Science Cluster

Sponsored by:

Eversana

Eversana

Pharma Intelligence

Pharma Intelligence

Moderator(s): Ms. Eleanor Malone - Editor in Chief, Pharma intelligence

Speaker(s):

Ms. Eleanor Malone - Editor in Chief, Pharma intelligence
Dr. Richard Stratford - CEO & Co-founder, OncoImmunity
Mr. Michael Engsig - CEO, Nykode Therapeutics
Dr. Holger Kissel - Vice President Business Alliances, BioNTech SE
Dr. Carl Kilander - Partner, HealthCap
Mr. Mike Ryan - Executive Vice President Europe, Eversana
Dr. Gunnveig Grødeland - Senior Scientist and Research Group Leader, University of Oslo

full program